Equifax (NYSE: EFX) CEO logs major option exercise and 10b5-1 stock sales

Rhea-AI Filing Summary

Equifax Inc. CEO and director Mark W. Begor reported multiple equity transactions dated 02/10/2026. He exercised a stock option for 37,791 shares of common stock at an exercise price of $112.46 per share and received a separate grant of 33,278 common shares at $0.0000.

On the same day, he executed a series of open-market sales of common stock at weighted average prices ranging from $192.8855 to $203.0792 per share, including blocks such as 11,000 and 18,352 shares. A further 1,759 shares were withheld at $202.71 to cover tax obligations.

After these transactions, Begor directly held 230,506 common shares and maintained additional indirect holdings through several GRAT vehicles, including 10,500, 21,284, 22,045, 12,333, and 16,287 shares. The sales were carried out under a Rule 10b5-1 trading plan adopted on 10/28/2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Begor Mark W

(Last) (First) (Middle)

1550 PEACHTREE STREET, N.W.

(Street)

ATLANTA GA 30309

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EQUIFAX INC [ EFX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		M(1)		37,791	A	$112.46	236,778(2)	D
Common Stock	02/10/2026		A		33,278	A	$0.0000	270,056(2)	D
Common Stock	02/10/2026		S(1)		201	D	$197.7889(3)	269,855(2)	D
Common Stock	02/10/2026		S(1)		213	D	$203.7607(4)	269,642(2)	D
Common Stock	02/10/2026		S(1)		227	D	$192.8855(5)	269,415(2)	D
Common Stock	02/10/2026		S(1)		331	D	$194.221(6)	269,084(2)	D
Common Stock	02/10/2026		S(1)		364	D	$195.3979(7)	268,720(2)	D
Common Stock	02/10/2026		S(1)		445	D	$196.428(8)	268,275(2)	D
Common Stock	02/10/2026		S(1)		829	D	$199.001(9)	267,446(2)	D
Common Stock	02/10/2026		F		1,759	D	$202.71	265,687(2)	D
Common Stock	02/10/2026		S(1)		1,772	D	$200.0293(10)	263,915(2)	D
Common Stock	02/10/2026		S(1)		4,057	D	$201.2626(11)	259,858(2)	D
Common Stock	02/10/2026		S(1)		11,000	D	$203.0792(12)	248,858(2)	D
Common Stock	02/10/2026		S(1)		18,352	D	$202.1545(13)	230,506(2)	D
Common Stock								10,500	I	2-yr 2025 GRAT
Common Stock								21,284	I	2-yr Dec 2025 GRAT
Common Stock								22,045	I	2-yr Jun 2025 GRAT
Common Stock								12,333	I	2-yr May 2025 GRAT
Common Stock								16,287	I	3-yr Jul 2024 GRAT

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option/Right to Buy	$112.46	02/10/2026		M			37,791	(14)	05/04/2028	Common Stock	37,791	$0.0000	113,374	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

2. Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

3. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $197.524 to $198.008, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

4. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $203.675 to $203.85, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

5. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $192.556 to $193.366, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

6. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $193.735 to $194.661, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

7. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $194.892 to $195.779, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

8. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $196.123 to $196.912, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

9. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $198.645 to $199.62, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

10. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $199.67 to $200.481, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

11. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $200.672 to $201.66, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

12. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $202.665 to $203.64, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

13. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $201.67 to $202.66, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

14. The option vested in three equal annual increments beginning 5/4/2019.

	/s/Lisa Stockard as Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Equifax (EFX) CEO Mark W. Begor report on this Form 4?

Mark W. Begor reported exercising stock options, receiving a stock grant, and selling Equifax common shares. The filing details option exercise, new share awards, open-market sales, tax-withholding share dispositions, and his resulting direct and indirect ownership positions in Equifax stock.

How many Equifax (EFX) shares did the CEO acquire through option exercise and grants?

Begor exercised options for 37,791 shares of Equifax common stock at $112.46 per share and received an additional 33,278 common shares at $0.0000. These transactions increased his direct holdings before subsequent sales and tax-withholding dispositions on the same date.

What Equifax (EFX) share sales did the CEO disclose, and at what prices?

Begor disclosed multiple open-market sales of Equifax common stock on 02/10/2026. Individual transactions ranged from 201 to 18,352 shares, with weighted average sale prices generally between $192.8855 and $203.0792 per share, as detailed in the Form 4 transaction table and related footnotes.

What does the tax-withholding transaction in the Equifax (EFX) Form 4 represent?

The Form 4 shows a code F transaction where 1,759 Equifax shares were disposed of at $202.71 per share. This reflects shares withheld to satisfy tax obligations related to equity awards, rather than an open-market sale initiated for portfolio purposes.

What is the Rule 10b5-1 trading plan noted in the Equifax (EFX) CEO’s filing?

The filing states that the reported sales were effected under a Rule 10b5-1 trading plan adopted on 10/28/2025. Such plans pre-schedule trades, allowing insiders to systematically sell shares according to predetermined instructions, helping separate trading decisions from later market-sensitive information.

What are the CEO’s indirect Equifax (EFX) holdings through GRATs?

In addition to direct holdings, Begor reports indirect ownership of Equifax shares through several grantor retained annuity trusts. These include positions of 10,500, 21,284, 22,045, 12,333, and 16,287 shares in distinct 2-year and 3-year GRAT structures identified by their respective start dates.

How many Equifax (EFX) options does the CEO hold after the reported exercise?

After exercising 37,791 stock options at $112.46, the Form 4 shows 113,374 derivative securities beneficially owned. These remaining stock options relate to Equifax common stock, with an expiration date of 05/04/2028 and prior vesting beginning on 05/04/2019.